Specialty pipeline forecast as of February 2009

[chantell.reagan]

The following list represents specialty pipeline updates for February 2009 from DrugPipelineForecast.com. In order to see these updates, you must be a registered user of DrugManagementForum (click here to register)

Actemra - approved in EU; resubmission of NDA planned

Ampligen - FDA review date extended

axitinib - negative Phase III data

Cayston - FDA upheld request for additional data

Cimzia for RA - NDA resubmission planned

denosumab - FDA accepts BLA submission

dirucotide - mixed Phase III results

ecallantide - advisory committee votes in favor

elesclomol - negative safety analysis

fampridine SR - positive Phase III data published

Onrigin - NDA submission (new entry in DrugPipelineForecast)

pirfenidone - positive Phase III data (new entry in DrugPipelineForecast)

Puricase - FDA review date extended

Stelara - EU approval

Zentase - FDA review date changed

For more information, or to search additional drugs, see DrugPipelineForecast.com